elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q35993104-3EDE1D81-D915-4864-BAA8-0AFE04D0E067
Q35993104-3EDE1D81-D915-4864-BAA8-0AFE04D0E067
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35993104-3EDE1D81-D915-4864-BAA8-0AFE04D0E067
Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.
P2860
Q35993104-3EDE1D81-D915-4864-BAA8-0AFE04D0E067
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35993104-3EDE1D81-D915-4864-BAA8-0AFE04D0E067
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2df6f7798d03702687b71402c191f0baab5ebf45
P2860
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.